Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Paclitaxel 15Carboplatin 15Taxes 9Cisplatin 8Topotecan 4Docetaxel 4Filgrastim 3pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Methods 2Gemcitabine 2GEN-1 2Etoposide 2Erlotinib Hydrochloride 2Educational Status 2Early Intervention, Educational 2Chemotherapy, Adjuvant 2vandetanib 1rilotumumab 1oregovomab 1motesanib diphosphate 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Watchful Waiting 1VTX-2337 1Trabectedin 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Fallopian Tube Neoplasms × GEN-1 × Clear all
NCT01489371 2019-03-12

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 1 Completed
16 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01118052 2018-01-11

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
22 enrolled 8 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡